全文获取类型
收费全文 | 8564篇 |
免费 | 569篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 194篇 |
妇产科学 | 123篇 |
基础医学 | 841篇 |
口腔科学 | 170篇 |
临床医学 | 761篇 |
内科学 | 2168篇 |
皮肤病学 | 80篇 |
神经病学 | 1177篇 |
特种医学 | 279篇 |
外科学 | 1561篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 344篇 |
眼科学 | 205篇 |
药学 | 454篇 |
中国医学 | 13篇 |
肿瘤学 | 739篇 |
出版年
2023年 | 110篇 |
2022年 | 94篇 |
2021年 | 351篇 |
2020年 | 230篇 |
2019年 | 301篇 |
2018年 | 311篇 |
2017年 | 237篇 |
2016年 | 272篇 |
2015年 | 287篇 |
2014年 | 412篇 |
2013年 | 497篇 |
2012年 | 761篇 |
2011年 | 711篇 |
2010年 | 366篇 |
2009年 | 362篇 |
2008年 | 544篇 |
2007年 | 534篇 |
2006年 | 547篇 |
2005年 | 451篇 |
2004年 | 407篇 |
2003年 | 360篇 |
2002年 | 308篇 |
2001年 | 63篇 |
2000年 | 57篇 |
1999年 | 65篇 |
1998年 | 35篇 |
1997年 | 35篇 |
1996年 | 39篇 |
1995年 | 29篇 |
1994年 | 34篇 |
1993年 | 29篇 |
1992年 | 39篇 |
1991年 | 39篇 |
1990年 | 21篇 |
1989年 | 35篇 |
1988年 | 21篇 |
1987年 | 15篇 |
1986年 | 20篇 |
1985年 | 17篇 |
1984年 | 27篇 |
1983年 | 17篇 |
1982年 | 13篇 |
1981年 | 17篇 |
1980年 | 8篇 |
1979年 | 12篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1975年 | 5篇 |
1974年 | 10篇 |
1973年 | 5篇 |
排序方式: 共有9190条查询结果,搜索用时 15 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
3.
4.
5.
6.
Filippo Pietrantonio Christian Cotsoglou Giovanni Fucà Salvatore Lo Vullo Federico Nichetti Massimo Milione Jorgelina Coppa Marta Vaiani Alessandra Alessi Michele Prisciandaro Michele Droz-Dit Busset Federica Morano Salvatore Corallo Silvia Lazzati Maria Antista Alessia Mennitto Giovanni Randon Alessandra Raimondi Vincenzo Mazzaferro 《Clinical colorectal cancer》2019,18(1):34-43.e6
Background
In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.Patients and Methods
This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Patients received 5 preoperative and 4 postoperative cycles of biweekly COI-B (irinotecan 180 mg/m2 and bevacizumab 5 mg/Kg on day 1, oxaliplatin 85 mg/m2 on day 2, and capecitabine 1000 mg/m2 twice a day on days 2 to 6). The primary endpoint was pathologic response rate in the intention-to-treat population. A Simon 2-stage design was adopted to detect an increase from 30% to 50% with a power of 90%. Dynamic imaging biomarkers (early tumor shrinkage [ETS], deepness of response, maximum standardized uptake volume [SUVmax]/regression index) and next generation sequencing data were explored as surrogates.Results
From June 2013 to March 2017, 46 patients were enrolled. Pathologic response was achieved in 63% patients (endpoint met), and responders achieved significantly better survival outcomes with respect to non-responders. The most frequent grade 3/4 adverse events were diarrhea and neutropenia (8.7%) in the preoperative phase and thromboembolic events (5.9%) in the postoperative phase. ETS and lower SUV-2 were significantly associated with pathologic response.Conclusion
The COI-B regimen is a feasible and highly active perioperative strategy in patients with molecularly unselected, potentially resectable CRCLM. ETS and SUV-2 have a promising role as imaging-based biomarkers for pathologic response. 相似文献7.
8.
Federico Cagnazzo Davide Tiziano Di Carlo Giandomenico Petrella Paolo Perrini 《Neurosurgical review》2020,43(2):397-406
The risk of ventriculostomy-related hemorrhage among patients requiring antiplatelet therapy (AT) for the endovascular treatment of acutely ruptured intracranial aneurysms needed further investigation. The authors performed a systematic review and meta-analysis of the literature examining the EVD-related hemorrhage rate among patients with and without AT (controls). According to PRISMA guidelines, a comprehensive review of studies published between January 1990 and April 2018 was carried out. The authors identified series with > 5 patients reporting the EVD-associated hemorrhage rate among the AT group and the control group. Variables influencing outcomes were analyzed using a random-effects meta-analysis model. We included 13 studies evaluating 516 (with AT) and 647 (without AT) patients requiring ventriculostomy. EVD-related hemorrhage rates were higher among the AT group (125/516 = 20.9%, 95% CI = 11.9–30%, I2 = 90% vs 57/647 = 9%, 95% CI = 5.5–12.5%, I2 = 45.8%) (p < 0.0001). Major EVD-associated hemorrhage rates were low in both the AT and control group (25/480 = 4.4%, 95% CI = 1.7–7.7%, I2 = 53.9% vs 6/647 = 0.7%, 95% CI = 0.03–1.7%, I2 = 0%) (p < 0.0001). Ventriculostomy before embolization and intraprocedural AT were associated with lower rates of EVD-related bleeding (32/230 = 9.6%, 95% CI = 2.1–17.1%, I2 = 75.4% vs 6/24 = 25.1%, 95% CI = 8.8–41%, I2 = 0%) (p < 0.02). The rate of major hemorrhage was higher after dual AT (CP + ASA) compared to single AT (ASA or CP) used as an intraprocedural loading dose (13/173 = 7%, 95% CI = 3.3–10.7%, I2 = 0% vs 6/210 = 1.7%, 95% CI = 0.1–3.4%, I2 = 0%) (p < 0.009). AT during endovascular treatment of acutely ruptured intracranial aneurysms increases the risk of EVD-related hemorrhages, although most of them are small and asymptomatic. When ventriculostomy is performed before endovascular procedures requiring antiplatelet administration, the hemorrhagic risk is minimized. A single antiplatelet therapy is associated with a lower rate of major bleeding than a dual therapy. 相似文献
9.